Xilong Scientific Co., Ltd. (SHE:002584)
China · Delayed Price · Currency is CNY 8.69
-0.01 (-0.11%)
Feb 13, 2026, 3:04 PM CST
Xilong Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,136 | 7,803 | 7,078 | 6,176 | 5,372 | 6,235 |
Other Revenue | 13.86 | 13.86 | 13.73 | 7.27 | 8.12 | 8.18 |
| 7,150 | 7,816 | 7,092 | 6,183 | 5,380 | 6,243 | |
Revenue Growth (YoY) | -1.94% | 10.22% | 14.69% | 14.93% | -13.83% | 87.05% |
Cost of Revenue | 6,635 | 7,294 | 6,632 | 5,756 | 4,856 | 5,787 |
Gross Profit | 514.92 | 522.88 | 459.7 | 426.78 | 523.64 | 456.34 |
Selling, General & Admin | 254.38 | 243.65 | 234.82 | 211.47 | 240.76 | 251.47 |
Research & Development | 94.41 | 109.9 | 95.7 | 90.47 | 118.97 | 102.72 |
Other Operating Expenses | 4.21 | -3.54 | 5.75 | 17.19 | 16.02 | 14.08 |
Operating Expenses | 374.79 | 361.49 | 344.61 | 331.92 | 395.75 | 381.31 |
Operating Income | 140.12 | 161.39 | 115.1 | 94.86 | 127.88 | 75.04 |
Interest Expense | -46.44 | -46.21 | -60.86 | -49.08 | -67.5 | -65.09 |
Interest & Investment Income | 6.82 | 5.38 | 6.7 | 92.1 | 144.18 | 12.52 |
Currency Exchange Gain (Loss) | -3.25 | -3.25 | -4.38 | -9.5 | 1.3 | 17.89 |
Other Non Operating Income (Expenses) | -139.22 | -28.17 | -13.96 | -29.59 | -7.76 | -3.56 |
EBT Excluding Unusual Items | -46.36 | 89.15 | 42.6 | 98.79 | 198.11 | 36.79 |
Impairment of Goodwill | - | - | -6.54 | - | - | -11.95 |
Gain (Loss) on Sale of Investments | 0.25 | 0.02 | - | 0 | - | -0.36 |
Gain (Loss) on Sale of Assets | -0.85 | -0.84 | 0.21 | -0.14 | -0.39 | 43.94 |
Asset Writedown | -4.61 | -6.32 | -0.5 | -1.47 | 0.34 | -0.66 |
Other Unusual Items | -7.14 | -9.72 | 7.15 | 5.57 | 11.04 | 13.49 |
Pretax Income | -58.71 | 72.29 | 42.92 | 102.74 | 209.1 | 81.25 |
Income Tax Expense | 4.24 | 9.3 | 8.33 | 15.04 | 7.98 | 17.56 |
Earnings From Continuing Operations | -62.96 | 62.99 | 34.59 | 87.69 | 201.12 | 63.69 |
Minority Interest in Earnings | -1.29 | -1.22 | -1.24 | 1.37 | -14.06 | -6.81 |
Net Income | -64.24 | 61.77 | 33.35 | 89.06 | 187.06 | 56.87 |
Net Income to Common | -64.24 | 61.77 | 33.35 | 89.06 | 187.06 | 56.87 |
Net Income Growth | - | 85.24% | -62.56% | -52.39% | 228.91% | 47.62% |
Shares Outstanding (Basic) | 561 | 562 | 556 | 594 | 534 | 569 |
Shares Outstanding (Diluted) | 561 | 562 | 556 | 594 | 534 | 569 |
Shares Change (YoY) | 1.68% | 1.04% | -6.39% | 11.09% | -6.02% | 3.33% |
EPS (Basic) | -0.11 | 0.11 | 0.06 | 0.15 | 0.35 | 0.10 |
EPS (Diluted) | -0.11 | 0.11 | 0.06 | 0.15 | 0.35 | 0.10 |
EPS Growth | - | 83.33% | -60.00% | -57.14% | 250.00% | 42.86% |
Free Cash Flow | 374.57 | 257.23 | -499.96 | -514.59 | 316.27 | 6.33 |
Free Cash Flow Per Share | 0.67 | 0.46 | -0.90 | -0.87 | 0.59 | 0.01 |
Dividend Per Share | - | 0.033 | 0.020 | - | - | - |
Dividend Growth | - | 65.00% | - | - | - | - |
Gross Margin | 7.20% | 6.69% | 6.48% | 6.90% | 9.73% | 7.31% |
Operating Margin | 1.96% | 2.07% | 1.62% | 1.53% | 2.38% | 1.20% |
Profit Margin | -0.90% | 0.79% | 0.47% | 1.44% | 3.48% | 0.91% |
Free Cash Flow Margin | 5.24% | 3.29% | -7.05% | -8.32% | 5.88% | 0.10% |
EBITDA | 183.47 | 203.36 | 155.22 | 130.97 | 157.56 | 104.93 |
EBITDA Margin | 2.57% | 2.60% | 2.19% | 2.12% | 2.93% | 1.68% |
D&A For EBITDA | 43.35 | 41.97 | 40.13 | 36.11 | 29.68 | 29.9 |
EBIT | 140.12 | 161.39 | 115.1 | 94.86 | 127.88 | 75.04 |
EBIT Margin | 1.96% | 2.07% | 1.62% | 1.53% | 2.38% | 1.20% |
Effective Tax Rate | - | 12.86% | 19.41% | 14.64% | 3.82% | 21.61% |
Revenue as Reported | 7,150 | 7,816 | 7,092 | 6,183 | 5,380 | 6,243 |
Advertising Expenses | - | 3.85 | 0.39 | 3.73 | 0.97 | 0.67 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.